Browsing Tag
Telix Pharmaceuticals Limited
9 posts
Telix Pharmaceuticals (TLX) gains European review momentum for TLX101-Px brain cancer imaging candidate
Telix has a glioma imaging gap to fill. Europe’s TLX101-Px review could test whether radiopharma can move beyond prostate cancer.
What manufacturing scale-up means for REYOBIQ’s regulatory and clinical trajectory
Explore how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing and what it means for regulatory approval and clinical success.
Can Moleculin Biotech, Inc. translate preclinical pancreatic cancer signals into clinical impact?
Explore how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing and what it means for regulatory approval and clinical success.
Could Pixclara become the missing imaging tool in U.S. glioma care after FDA NDA acceptance?
Could Pixclara transform U.S. glioma imaging after FDA NDA acceptance? Explore what Telix Pharmaceuticals Limited’s September catalyst could change next.
Telix Pharmaceuticals (ASX: TLX) jumps 16% after CMS greenlight and Illuccix’s European rollout
Telix Pharmaceuticals raises FY25 revenue guidance after securing CMS reimbursement for Gozellix and accelerating Illuccix's launch in Europe. Learn what’s next.
Telix Pharmaceuticals gains U.S. Medicare reimbursement code for Gozellix prostate cancer imaging agent
Telix Pharmaceuticals’ Gozellix secures U.S. reimbursement code, opening access to PSMA-PET prostate cancer imaging. Find out what’s next for its rollout and impact.
Top US stock losers on April 28, 2025: Spotify, Schneider Electric, Goosehead Insurance lead broad market retreat
Top US stocks fell sharply on April 28, with Spotify, Schneider Electric, and Goosehead Insurance leading declines. Find out why these stocks dropped.
Wall Street rally: Pegasystems, Summit Therapeutics among top gainers as trade optimism lifts US stocks
Find out how Pegasystems, Summit Therapeutics, and Tempus AI surged on April 23, 2025, as tariff cuts and AI optimism drove major gains across US stock markets.
Brain cancer breakthrough? Telix Pharmaceuticals’ TLX101 boosts survival in early study as stock outlook strengthens
Discover how Telix’s TLX101 therapy is showing new promise for brain cancer as investor sentiment rises with key study results and clinical trial expansion.